Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.

Annals of plastic surgery 2026 Vol.96(3) p. 272-276

Menkü Özdemir FD, Uzun H

관련 도메인

Abstract

Skin redundancy after massive weight loss often requires body contouring procedures such as abdominoplasty and mastopexy. Bariatric patients may face higher complication risks due to nutritional deficiencies. However, with proper management, including stable body weight and adequate nutritional status, these risks may be mitigated. In addition, glucagon-like peptide-1 (GLP-1) receptor agonists have recently emerged as a rising trend for nonbariatric weight loss, but their impact on surgical outcomes remains underexplored. Between January 2015 and August 2025, 101 consecutive weight-loss patients undergoing synchronous full abdominoplasty and mastopexy with a superomedial pedicle were prospectively enrolled. Forty-nine patients had undergone bariatric surgery, whereas 52 achieved weight loss without bariatric surgery, including 14 patients using GLP-1 receptor agonists (liraglutide or tirzepatide). Demographic characteristics, weight loss parameters, serum albumin levels, operative details, and complications (classified by Clavien-Dindo) were recorded. There were no significant differences between groups in age or BMI. The bariatric group demonstrated significantly greater absolute and percentage weight loss, although serum albumin levels were slightly lower compared to nonbariatric patients. The overall complication rate was 8.9%, with no life-threatening events (Clavien-Dindo grades IV and V). Complication rates did not differ significantly between bariatric and nonbariatric patients. Notably, no complications occurred in patients who lost weight with GLP-1 analogs. In conclusion, synchronous abdominoplasty and mastopexy can be performed safely in bariatric patients who maintain stable body weight for at least 6 months and have serum albumin level of >3.5 g/dL. The increasing use of GLP-1 analogs in nonbariatric weight-loss patients represents an important emerging trend that warrants further investigation in the context of body contouring surgery.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 mastopexy 유방성형술 dict 4
시술 abdominoplasty 복부성형술 dict 4
해부 Skin scispacy 1
해부 body scispacy 1
해부 serum albumin scispacy 1
약물 liraglutide C1456408
liraglutide
scispacy 1
질환 weight loss C1262477
Weight Loss
scispacy 1
질환 nutritional deficiencies C0162429
Malnutrition
scispacy 1
기타 Patients scispacy 1
기타 GLP-1 → glucagon-like peptide-1 scispacy 1
기타 glucagon-like peptide-1 scispacy 1
기타 superomedial pedicle scispacy 1
기타 GLP-1 receptor agonists scispacy 1

MeSH Terms

Humans; Abdominoplasty; Female; Weight Loss; Bariatric Surgery; Prospective Studies; Adult; Middle Aged; Male; Mammaplasty; Treatment Outcome; Glucagon-Like Peptide 1; Obesity, Morbid

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문